COVID-19 and cancer: do we really know what we think we know?

Nat Rev Clin Oncol. 2020 Jul;17(7):386-388. doi: 10.1038/s41571-020-0394-y.

Abstract

Early published data on COVID-19 in patients with cancer are being referenced in clinical guidelines, despite methodological flaws that limit the quality of much of this evidence. In the next phase of research in this area, we argue that the quality of observational evidence should be prioritized over speed of publication.

MeSH terms

  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity*
  • COVID-19
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / immunology
  • Coronavirus Infections / therapy*
  • Coronavirus Infections / virology
  • Data Accuracy
  • Evidence-Based Medicine / standards*
  • Health Status
  • Host-Pathogen Interactions
  • Humans
  • Immunocompromised Host
  • Medical Oncology / standards*
  • Neoplasms / diagnosis
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Opportunistic Infections / diagnosis
  • Opportunistic Infections / immunology
  • Opportunistic Infections / therapy*
  • Opportunistic Infections / virology
  • Pandemics
  • Patient Safety
  • Periodicals as Topic / standards
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / therapy*
  • Pneumonia, Viral / virology
  • Practice Guidelines as Topic / standards*
  • Prognosis
  • Risk Factors
  • SARS-CoV-2